REGENERON PHARMACEUTICALS INC. - COMMON STOCK
712.33
31-十二月-24 16:45:00
15 分钟延时
股票
+9.74
+1.39%
今日范围
703.39 - 713.00
ISIN
N/A
来源
NASDAQ
-
29 4月 2024 07:00:18 条件 Nasdaq GlobeNewswire
-
25 4月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
24 4月 2024 10:05:18 条件 Nasdaq GlobeNewswire
-
22 4月 2024 17:54:01 条件 Nasdaq GlobeNewswire
-
07 4月 2024 16:00:12 条件 Nasdaq GlobeNewswire
-
01 4月 2024 16:05:00 条件 Nasdaq GlobeNewswire
-
Regeneron Provides Update on Biologics License Application for Odronextamab
25 3月 2024 07:00:02 条件 Nasdaq GlobeNewswire
-
11 3月 2024 07:00:23 条件 Nasdaq GlobeNewswire
-
08 3月 2024 07:00:26 条件 Nasdaq GlobeNewswire
-
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
28 2月 2024 09:48:56 条件 NetDania Notify
-
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
26 2月 2024 09:48:37 条件 NetDania Notify
-
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
23 2月 2024 09:45:04 条件 NetDania Notify
-
23 2月 2024 01:00:00 条件 Nasdaq GlobeNewswire
-
21 2月 2024 07:00:13 条件 Nasdaq GlobeNewswire
-
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
16 2月 2024 00:59:00 条件 Nasdaq GlobeNewswire
-
Regeneron Announces Investor Conference Presentations
06 2月 2024 16:05:00 条件 Nasdaq GlobeNewswire
-
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
02 2月 2024 09:45:10 条件 NetDania Notify
-
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
02 2月 2024 06:30:01 条件 Nasdaq GlobeNewswire
-
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
02 2月 2024 06:00:04 条件 Nasdaq GlobeNewswire